[go: up one dir, main page]

MX2016010482A - Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. - Google Patents

Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.

Info

Publication number
MX2016010482A
MX2016010482A MX2016010482A MX2016010482A MX2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A
Authority
MX
Mexico
Prior art keywords
treatment
combination
proliferative disease
cancer
pi3k inhibitor
Prior art date
Application number
MX2016010482A
Other languages
English (en)
Inventor
Massacesi Cristian
- Caroline GERMA Marie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016010482A publication Critical patent/MX2016010482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación farmacéutica que comprende: ((a) un inhibidor específico de la isoforma alfa de la fosfatidilinositol-3-quinasa 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridi n-4-il]tiazol-2-il}-amida) del ácido (S)-pirrolidin-1,2-dicarboxíl ico o cualquier sal farmacéuticamente aceptable del mismo (b) un inhibidor de mTOR y (c) exemestano o cualquier sal farmacéuticamente aceptable del mismo, en particular para uso en el tratamiento o prevención de una enfermedad proliferativa; usos de tal combinación en la preparación de un medicamento para el tratamiento o prevención de una enfermedad proliferativa; composiciones farmacéuticas de la combinación de dichos agentes terapéuticos y métodos de tratamiento de una enfermedad proliferativa en un sujeto que comprende administrar a dicho sujeto una cantidad terapéuticamente eficaz de una combinación de este tipo.
MX2016010482A 2014-02-11 2015-02-10 Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. MX2016010482A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305179 2014-02-11
PCT/IB2015/050993 WO2015121795A1 (en) 2014-02-11 2015-02-10 Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2016010482A true MX2016010482A (es) 2016-10-17

Family

ID=50115790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010482A MX2016010482A (es) 2014-02-11 2015-02-10 Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.

Country Status (11)

Country Link
US (2) US20170165246A1 (es)
EP (1) EP3104890A1 (es)
JP (1) JP2017505345A (es)
KR (1) KR20160110963A (es)
CN (1) CN106061505A (es)
AU (2) AU2015216590A1 (es)
BR (1) BR112016014903A8 (es)
CA (1) CA2937504A1 (es)
MX (1) MX2016010482A (es)
RU (1) RU2016135413A (es)
WO (1) WO2015121795A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111150848B (zh) * 2020-01-21 2022-02-15 中国药科大学 Plagl2及其在肝癌中的应用
WO2024148225A1 (en) * 2023-01-05 2024-07-11 Ks And Associates Llc, Doing Business As Dream Tech, Llc Method and system for prior toxicity data informed dose-response modeling and benchmark dose (bmd) estimation
US20250295666A1 (en) * 2024-03-22 2025-09-25 Certis Oncology Solutions, Inc. Pi3k-alpha inhibitor and mtor inhibitor combinations for cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20140066474A1 (en) * 2011-04-25 2014-03-06 Novartis Ag Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy

Also Published As

Publication number Publication date
RU2016135413A3 (es) 2018-11-16
CA2937504A1 (en) 2015-08-20
AU2017251804A1 (en) 2017-11-16
US20170165246A1 (en) 2017-06-15
US20180353495A1 (en) 2018-12-13
EP3104890A1 (en) 2016-12-21
JP2017505345A (ja) 2017-02-16
BR112016014903A8 (pt) 2018-05-02
WO2015121795A1 (en) 2015-08-20
BR112016014903A2 (pt) 2017-08-08
AU2015216590A1 (en) 2016-06-30
CN106061505A (zh) 2016-10-26
KR20160110963A (ko) 2016-09-23
RU2016135413A (ru) 2018-03-14

Similar Documents

Publication Publication Date Title
MX2015017629A (es) Combinaciones farmaceuticas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
IN2015DN00376A (es)
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
IN2015DN00450A (es)
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2015035410A8 (en) Cancer therapy
RU2017111848A (ru) Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
BR112015012497A2 (pt) combinações farmacêuticas
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.